NO20063856L - Behandling av psykoser med quetiapin-antipsykotiske midler - Google Patents

Behandling av psykoser med quetiapin-antipsykotiske midler

Info

Publication number
NO20063856L
NO20063856L NO20063856A NO20063856A NO20063856L NO 20063856 L NO20063856 L NO 20063856L NO 20063856 A NO20063856 A NO 20063856A NO 20063856 A NO20063856 A NO 20063856A NO 20063856 L NO20063856 L NO 20063856L
Authority
NO
Norway
Prior art keywords
psychoses
quetiapine
antipsychotics
treatment
methods
Prior art date
Application number
NO20063856A
Other languages
English (en)
Norwegian (no)
Inventor
Robin Mccoy
Margaret Minkwitz
Jamie Mullen
Ellis Wilson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20063856L publication Critical patent/NO20063856L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
NO20063856A 2004-01-30 2006-08-29 Behandling av psykoser med quetiapin-antipsykotiske midler NO20063856L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54061804P 2004-01-30 2004-01-30
PCT/SE2005/000094 WO2005072742A1 (en) 2004-01-30 2005-01-27 Treatment of psychoses with quetiapine antipsychotic

Publications (1)

Publication Number Publication Date
NO20063856L true NO20063856L (no) 2006-10-26

Family

ID=34826230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063856A NO20063856L (no) 2004-01-30 2006-08-29 Behandling av psykoser med quetiapin-antipsykotiske midler

Country Status (13)

Country Link
US (2) US20050171088A1 (enExample)
EP (1) EP1713488A1 (enExample)
JP (1) JP2007520488A (enExample)
KR (1) KR20070011276A (enExample)
CN (1) CN1913902A (enExample)
AU (1) AU2005209142A1 (enExample)
BR (1) BRPI0507086A (enExample)
CA (1) CA2495361A1 (enExample)
IL (1) IL176999A0 (enExample)
NO (1) NO20063856L (enExample)
RU (1) RU2006130687A (enExample)
WO (1) WO2005072742A1 (enExample)
ZA (1) ZA200606128B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (en) 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
CN102631350B (zh) * 2012-03-29 2013-10-16 南京正科制药有限公司 一种富马酸喹硫平与鲁拉西酮的复方制剂
CN102716133A (zh) * 2012-04-06 2012-10-10 中国人民解放军第三军医大学 喹硫平在制备预防和治疗自身免疫性疾病的药物中的应用
CN109464451B (zh) * 2019-01-15 2021-07-13 范崇桂 一种治疗神经衰弱的药物及其制备方法
RU2717939C1 (ru) * 2019-10-29 2020-03-27 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ лечения интоксикационных психозов при острых отравлениях психоактивными веществами

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6194466B1 (en) * 1998-10-15 2001-02-27 Elizabeth Marie Cottingham Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
US20030096808A1 (en) * 1999-03-29 2003-05-22 Jon M. Miller Substance to prevent or reverse weight gain induced by psychoactive agents
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
DE60219761T2 (de) * 2001-02-06 2008-01-17 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
US6621096B2 (en) * 2001-05-21 2003-09-16 Hewlett-Packard Develpoment Company, L.P. Device isolation process flow for ARS system
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20040204469A1 (en) * 2001-06-19 2004-10-14 Norbert Muller Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
CN1547473A (zh) * 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
CA2494109A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050171139A1 (en) * 2003-10-07 2005-08-04 Hammer Ronald P.Jr. Treating psychotic symptoms
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0417749A (pt) * 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
CA2556160A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US8285900B2 (en) * 2009-02-17 2012-10-09 The Board Of Regents Of The University Of Texas System Method and apparatus for congestion-aware routing in a computer interconnection network

Also Published As

Publication number Publication date
BRPI0507086A (pt) 2007-06-19
EP1713488A1 (en) 2006-10-25
KR20070011276A (ko) 2007-01-24
IL176999A0 (en) 2006-12-10
CA2495361A1 (en) 2005-07-30
ZA200606128B (en) 2007-11-28
US20050171088A1 (en) 2005-08-04
US20100311718A1 (en) 2010-12-09
RU2006130687A (ru) 2008-03-10
AU2005209142A1 (en) 2005-08-11
WO2005072742A1 (en) 2005-08-11
JP2007520488A (ja) 2007-07-26
CN1913902A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
NO20075304L (no) Metode for avtagende forkalkning
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201070422A1 (ru) Производные оксадиазола
NO20092637L (no) Fremgangsmater for behandling
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201100393A1 (ru) Применение усиливающих агентов, возможно связанных с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
DE602005023587D1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20071378L (no) Tiazolo-naftylsyrer.
NO20083436L (no) Kjemisk papirmassebehandling, sammensetning og metoder
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
IL198922A0 (en) Chemical compounds and uses
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE552251T1 (de) Thiophen- und furanverbindungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application